Pfizer and the associated logos are trademarks of Pfizer Inc.

Pfizer Inc. is a global biopharmaceutical company driven by innovation and a mission to deliver breakthroughs that change patients’ lives. With deep expertise in inflammation, metabolic disease, and rare disorders, Pfizer is increasingly focused on addressing the growing burden of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH)—conditions at the intersection of metabolic dysregulation and chronic inflammation.

Pfizer’s strategy in MASH centers on targeted, mechanism-based therapies that aim to modify disease progression at multiple levels, including lipid accumulation, immune response, and fibrogenesis. The company’s investigational agents include modulators of lipid metabolism pathways, anti-inflammatory mechanisms, and fibrotic signaling, reflecting a multi-faceted approach to the complex pathophysiology of MASH.

In addition to internal development, Pfizer leverages a collaborative R&D model—partnering with academic institutions, biotech firms, and digital health innovators—to accelerate therapeutic discovery and precision diagnostics for MASH and related metabolic syndromes. These partnerships support the advancement of novel biomarkers, non-invasive monitoring tools, and combination regimens that address both liver-specific pathology and systemic cardiometabolic risk.

With a legacy of leadership in chronic disease management and a robust pipeline spanning small molecules, biologics, and combination therapies, Pfizer is committed to advancing transformative treatments for patients with MASH. By integrating innovation, data-driven insights, and global reach, Pfizer is helping to shape the future of liver care for the millions affected by MASLD and its complications.